

1 TITLE PAGE

2 Impact of SARS-CoV-2 pandemic among health care workers in a 3 secondary teaching hospital in Spain.

4

5 Javier Garralda Fernandez^{1¶}, Ignacio Molero Vilches^{1¶}, Alfredo Bermejo
6 Rodríguez^{1,4&}, Isabel Cano Torres^{1¶}, Elda I. Colino Romay², Isabel García
7 Arata^{1¶}, Jerónimo Jaqueti Aroca^{1¶}, Rosa Lillo^{1¶}, Daniel Lopez Lacomba¹, Luis
8 Mazón², Laura Molina Esteban^{1¶}, Luis J Morales García^{1¶}, Laura Moratilla
9 Monzo^{3,4&}, Elva Nieto-Borrajo^{1¶}, Maria Pacheco Delgado^{1¶}, Santiago Prieto
10 Menchero^{1¶}, Cristina Sánchez Hernández^{1¶}, Eva Sánchez Testillano², Jesús
11 García-Martínez^{1,5*&}

12

13 ¹Laboratory Medicine, Hospital Universitario de Fuenlabrada, Fuenlabrada,
14 Spain.

15 ²Occupational Health Service, Hospital Universitario de Fuenlabrada,
16 Fuenlabrada, Spain.

17 ³Preventive Medicine Service, Hospital Universitario de Fuenlabrada,
18 Fuenlabrada, Spain.

19 ⁴Health Sciences Faculty. Universidad Rey Juan Carlos. Spain

20 ⁵Escuela Internacional de Doctorado. Universidad Rey Juan Carlos. Spain.

21

22 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Corresponding author

23 E-mail: jgmartinez@salud.madrid.org (JGM)

24

25 ¶These authors contributed equally to this work.

26 &These authors also contributed equally to this work.

27

28 **Abstract**

29 Background. The COVID-19 pandemic has posed a huge challenge to
30 healthcare systems and their personnel worldwide. The study of the impact of
31 SARS-CoV-2 infection among healthcare workers, through prevalence studies,
32 will let us know viral expansion, individuals at most risk and the most exposed
33 areas. The aim of this study is to gauge the impact of SARS-CoV-2 pandemic in
34 our hospital workforce and identify groups and areas at increased risk.

35 Methods and Findings. This is a cross-sectional and longitudinal study carried
36 out on healthcare workers based on molecular and serological diagnosis of
37 SARS-CoV-2 infection. Of the 3013 HCW invited to participate, finally 2439
38 (80.9%) were recruited, including 674 (22.4%) who had previously consulted at
39 the OHS for confirmed exposure and/or presenting symptoms suggestive of
40 COVID-19. A total of 411 (16.9%) and 264 (10.8%) healthcare workers were
41 SARS-CoV-2 IgG and rRT-PCR positive, respectively. The cumulative
42 prevalence considering all studies (IgG positive HCW and/or rRT-PCR positive
43 detection) has been 485 (19.9%). SARS-CoV-2 IgG-positive patients in whom the
44 virus was not detected were 221 (9.1%); up to 151 of them (68.3%) did not report
45 any compatible symptoms nor consult at the OHS for this reason. Men became
46 more infected than women (25% vs 18.5%, $p=0.0009$), including when data were
47 also classified by age. COVID-19 cumulative prevalence among the HCW
48 assigned to medical departments was higher (25.2%) than others, as well as
49 among medical staff (25.4%) compared with other professional categories
50 ($p<0.01$).

51

52 Conclusions. Global impact of the COVID-19 pandemic on HCW of our centre
53 has been 19.9%. Doctors and medical services personnel have had the highest
54 prevalence of SARS-CoV-2 infection, but many of them have not presented
55 compatible symptoms. This emphasizes the performance of continuous
56 surveillance methods of the most exposed health personnel and not only based
57 on the appearance of symptoms.

58

59 **Introduction**

60 At the end of 2019 a cluster of patients with a severe respiratory syndrome,
61 whose cause was finally identified as a new coronavirus (SARS-CoV-2)[1],
62 emerged in the Chinese city of Wuhan. In January 2020, World Health
63 Organization issued a statement for an international emergency outbreak and on
64 March 11, 2020 declared COVID-19 a pandemic[2].

65 This new virus is mainly spread by secretions and respiratory droplets, thus
66 close contact is the main way of infection, although it could also occur by other
67 means as fomites and contaminated surfaces[3]. Asymptomatic carriers may play
68 an important role and contribute to the disease spread too[4]. The mean
69 incubation period is 5.1 days (95% CI, 4.5 to 5.8 days)[5] and the basic
70 reproductive number was estimated to be between 2.8 and 3.3[6].

71 Healthcare workers (HCW) are at high risk of infection and a source of
72 transmission for patients and other staff. In China, more than 2000 cases among
73 health personnel were infected as of February, most in Hubei province[7]. In
74 March 2020, Italy reported 2600 infections and more than 40 deaths among HCW
75 population[8]. In Spain, since the beginning of the pandemic up to May 11, 40921

76 cases were reported to the national epidemiological surveillance network[9], they
77 were mainly women (76.5%) and had an average age of 46 years (36-55). Most
78 of them presented cough (69.6%), fever (65.9%) and sore throat (39.6%). Four
79 thousand one hundred seventy seven (10.5%) required hospitalization and 310
80 (1.1%) intensive care; up to 53 HCW have died. These events have resulted in
81 lack of health personnel and, therefore, an additional burden in the fight against
82 the pandemic.

83 Health personnel are critical and have become a weak point of the health
84 system in this pandemic. Seroprevalence studies allow estimating the individual
85 and areas at greatest risk. This information is relevant to implement approaches
86 to promote HCW safety and adequately manage resources in future outbreaks.

87 The aim of this study is to gauge the impact of SARS-CoV-2 pandemic in our
88 hospital workforce and identify groups and areas at increased risk.

89 **Materials and methods**

90 **Setting**

91 This is a cross-sectional and longitudinal study carried out with HCW from
92 the Hospital Universitario de Fuenlabrada. The hospital is located in the
93 municipality of Fuenlabrada, south of the metropolitan area of Madrid (Spain),
94 and it has assigned a population of about 225,000 inhabitants from the towns of
95 Fuenlabrada, Moraleja de Enmedio and Humanes[10].

96 **Design and analytical methods**

97 The cross-sectional study was carried out between April 14 and May 13, 2020
98 and included all HCW who came from different hospital services and belonged to
99 all professional categories (administrative and auxiliary services staff, central
100 services technicians, cleaning staff, clinic assistants, doctors, nurses and
101 watchmen). All HCW were invited to participate, recruited from hospital Human
102 Resources database (as of April 10, 2020) by the Occupational Health Service
103 (OHS) and summoned by the Admission Service coordinated with the hospital's
104 Laboratory Medicine to perform the tests. A nasopharyngeal swab and venous
105 blood sample were obtained simultaneously from all participants for molecular
106 and serological diagnosis of SARS-CoV-2 infection, respectively. Both samples
107 were sent during the next hour after collection and processed at the Medicine
108 Laboratory. Nasopharyngeal samples were collected with flocked swabs in a viral
109 transport medium that contains guanidine salts to inactivate and preserve the
110 virus (Mole Bioscience, Taizhou, China). Nucleic acid extraction was performed
111 in the QIA Symphony SP instrument with the QIA Symphony DSP Virus/Pathogen
112 Midi Kit (Qiagen, Hilden, Germany) from 400 µl of sample or manually using the
113 High Pure RNA Isolation Kit (Roche Diagnostics GmbH, Mannheim, Germany)
114 from 200 µl of sample. Molecular detection was carried out by rRT-PCR in a
115 LightCycler 480 System (Roche Diagnostics GmbH, Mannheim, Germany) using
116 the LightMix® Modular SARS-CoV (COVID19) kit (Roche Diagnostics GmbH,
117 Mannheim, Germany). Positive and negative controls as well as an internal
118 control (LightMix® Modular EAV RNA Extraction Control) were included in each
119 run. Serum IgG and IgM antibody directed against SARS-CoV-S (spike) and
120 SARS-CoV-N (nucleocapside) recombinant antigens were measured in the
121 Maglumi 2000 platform (Snibe diagnostic, Shenzhen, China) with the Maglumi
122 2019-nCoV (SARS-CoV-2) IgM and IgG kits in a fully automated

123 chemiluminescence immunoassay (CLIA). The results were expressed in AU/mL
124 and considered positive or negative following manufacturer's instructions. Once
125 the rRT-PCR and the immunological study were analysed, a COVID status
126 assessment report was prepared for each HCW, in which the clinical situation
127 and symptom onset dates (if any) were assessed together with the test results
128 carried out. A HCW was classified as asymptomatic if genetic material from
129 SARS-COV-2 and/or serum IgG anti SARS-CoV-2 was detected but did not
130 consult at the OHS due to compatible symptoms with COVID-19 infection[11].

131 The longitudinal study was carried out from the appearance of the first
132 confirmed COVID-19 case in the hospital March 2, 2020 until May 13, and
133 included those HCW who consulted at the OHS for confirmed exposure and/or
134 presenting symptoms suggestive of COVID19[11], as registered in the OHS
135 database. For molecular detection of SARS-CoV-2 infection at least one
136 nasopharyngeal swab was obtained in viral transport medium and processed as
137 stated previously. All these symptomatic workers were also included in the cross-
138 sectional study as participants.

139 The following variables were collected from the participants in both studies:
140 age, gender, assigned service, professional category and symptom onset dates
141 (if any), as registered in the OHS and Human Resources Service database and
142 HCW medical records.

143 **Statistical analysis**

144 Absolute and relative prevalences were described both for SARS-CoV-2 rRT-
145 PCR, IgG and IgM positive and negative cases and their combinations in
146 reference to the total population recruited in both studies. Cumulative prevalence

147 (IgG positive and/or rRT-PCR positive in any of both studies, as a proportion of
148 the total participant population) was also described grouping by sex, age, hospital
149 service and professional category. We have tested associations between
150 categorical variables using χ^2 test or Fischer's exact test and between continuous
151 variables with T-Student test. A p-value < 0.05 was considered significant. The
152 odds ratio was calculated to compare the prevalence rate between professional
153 categories.

154 **Ethical considerations**

155 The study has been independently evaluated and approved by the Research
156 Ethics Committee of the Hospital Universitario de Fuenlabrada (Internal Code
157 20/37)

158 **Results**

159 Of the 3013 HCW invited to participate in the cross-sectional study, finally
160 2439 (80.9%) were recruited, corresponding to 1911 females (78.4%) and 528
161 males (21.6%), with a mean age of 42.1 years (18-65). Six hundred and seventy
162 four HCW (22.4%) were included in the longitudinal study because they had
163 previously consulted at the OHS for confirmed exposure and/or presenting
164 symptoms suggestive of COVID-19; they were 550 females (81.6%) and 124
165 males (18.4%), with a mean age of 42.4 years (18-65).

166 In the cross-sectional study a total of 411 HCW (16.9%) were SARS-CoV-2
167 IgG positive and in 32 (1.3%) IgM was detected. Only 2 out of the latter were
168 confirmed as active SARS-CoV-2 infection by rRT-PCR, both with detectable IgG.
169 In 11 cases, IgG was not detected and the repetitions of the tests did not confirm


170 the infection, so they were considered IgM false positive results; in 19 cases with
171 detectable IgG, a past infection with residual persistence of IgM antibodies was
172 considered. So henceforth, IgM tests were not considered to determine the
173 impact of the infection in the study population. In this study a total of 19 out of
174 2439 (0.8%) HCW were rRT-PCR positive, 10 out of them had an IgG antibody
175 detectable simultaneously.

176 Among the 674 workers who consulted at the OHS, 245 active infections
177 (36.4%) were reported by rRT-PCR. They declared symptoms onset dates mostly
178 from March 1 to mid-April, although there have been cases from the last days of
179 February to the second week of May (Fig 1). Among the 429 HCW with negative
180 rRT-PCR, only 11 (2.6%) showed a positive IgG in the seroprevalence study.

181

182 **Figure 1. Epidemiologic curve from symptoms onset dates in relation to**
183 **cases diagnosed in Madrid.** Blue columns are the number of HCW from HUF
184 that declared COVID-19 compatible symptoms by date of symptom onset; red
185 line is rRT-PCR-based diagnosed cases by date of diagnosis in región of Madrid*;
186 green line is rRT-PCR-based diagnosed cases by date in HUF **.

187



188

189 HCW: healthcare workers; HUF: Hospital Universitario de Fuenlabrada.

190 *Source: based on RENAVE data[12]

191 **Source: based on own Laboratory Medicine data

192

193 In summary, a total of 264 workers out of 2439 (10.8%) with active SARS-
194 CoV-2 infection were detected by rRT-PCR. The combination of both studies has
195 resulted in the global impact of the epidemic among hospital HCW. As
196 summarized in Table 1, in 411 out of 2439 (16.9%) workers a serum IgG was
197 recovered, while in 264 (10.8%) rRT-PCR was detected positive. In 190 (7.8%)
198 HCW IgG and viral RNA were simultaneously detected. Most people with a
199 negative rRT-PCR were asymptomatic, including HCW who presented detectable
200 IgG, while those in who viral RNA was detected were mostly symptomatic. It is
201 noteworthy that there were 221 (9.1%) SARS-CoV-2 IgG-positive patients in
202 whom the virus was not detected by rRT-PCR; up to 151 of them (68.3%) did not
203 report any compatible symptoms nor consult at the OHS for this reason. Up to 74
204 workers (3%) with confirmed SARS-CoV-2 infection by rRT-PCR had not

205 achieved IgG seroconversion at the time the study finished. In brief, the overall
 206 cumulative prevalence considering all studies (IgG positive HCW and rRT-PCR
 207 positive detection without seroconversion) has been 485 infected HCW out of
 208 2439 (19.9%).

209

210 **Table 1. Prevalence of symptomatic and asymptomatic cases based on**
 211 **SARS-CoV-2 RT-PCR and IgG status.**

	IgG+ n (%)		IgG- n (%)		Total n (%)
	symptomatic	asymptomatic	symptomatic	asymptomatic	
rRT-PCR+	178 (93.7)	12 (6.3)	66 (89.2)	8 (10.8)	264 (10.8)
	190 (7.8)		74 (3.0)		
rRT-PCR-	70 (31.7)	151 (68.3)	287 (14.7)	1667 (85.3)	2175 (89.2)
	221 (9.1)		1954 (80.1)		
Total	248 (60.3)	163 (38.7)	353 (17.4)	1675 (82.6)	2439
	411 (16.9)		2028 (83.1)		

212

213 Significant differences have been detected when the prevalence data have
 214 been stratified by sex. As shown in Table 2, men became more infected than
 215 women (25% vs 18.5%, p=0.0009). When data were also classified by age, again
 216 the COVID19 epidemic has infected more men, particularly in the age group
 217 between 35 and 45 years (32.1% vs 17.7%) (Fig 2), although these differences
 218 were not significant (p=0.38).

219

220

221

222


223 **Table 2. Frequency of SARS-Cov-2 rRT-PCR and IgG result cases by sex.**

	Women n=1911 (%)	Men n=528 (%)	Total n=2439 (%)
PCR positive and IgG positive	142 (7.5%)	48 (9.1%)	190 (7.8%)
PCR positive and IgG negative	56 (2.9%)	18 (3.4%)	74 (3.0%)
PCR negative and IgG positive	155 (8.1%)	66 (12.5%)	221 (9.1%)
PCR negative and IgG negative	1558 (81.5%)	396 (75.0%)	1954 (80.1%)
IgG positive and/or PCR positive	353 (18.5%)	132 (25.0%)	485 (19.9%)

224 Sex differences in cumulative prevalence (IgG positive and/or RT-PCR positive) were significant
 225 (p=0.0009).

226

227 **Figure 2. Age and sex cumulative prevalence of SARS-CoV-2 cases (IgG**
 228 **positive and/or RT-PCR positive).**



229


230 The differences by age group were not significant.

231

232 In order to study the influence of work-related exposure to the virus into the
233 possibility of getting infected, HCW were classified according to their medical
234 department. Cumulative prevalence of SARS-CoV-2 among the HCW assigned
235 to the Internal Medicine, Emergency (ER) and Intensive Care Unit (ICU)
236 departments was higher (25.2%) than other departments (Fig 3). Personnel
237 assigned to auxiliary and administrative services were those with the lowest risk
238 of infection (13.7%). Difference between groups were statistically significant
239 ($p < 0.05$).

240

241 **Figure 3. Cumulative prevalence of SARS-CoV-2 cases (IgG positive and/or**
242 **RT-PCR positive) by hospital departments.**



243

244 Differences were significant ($p < 0.001$).


245

246 Finally, we analysed the influence of the staff category and the prevalence of
247 SARS-CoV-2 in our hospital. As shown in Fig 4, cumulative prevalence of SARS-
248 CoV-2 was higher among the medical staff (25.4%) compared with other

249 categories ($p < 0.01$). The odds of being infected by staff category was 2.13 (1.53-
250 2.96, $p < 0.0001$), 1.77 (1.26-2.49, $p = 0.0009$), 1.68 (1.02-2.78, $p = 0.0435$), 1.51
251 (1.09-2.09, $p = 0.0129$), 1.39 (0.87-2.21, $p = 0.1685$), and 1.27 (0.68-2.39,
252 $p = 0.4541$) for doctors, nurses assistants, watchmen, nurses, technicians, and
253 cleaning staff, respectively.

254

255 **Figure 4. Cumulative prevalence of SARS-CoV-2 cases (IgG positive and/or**
256 **RT-PCR positive) by professional category.**



257

258 Differences were significant ($p < 0.05$).

259

260 Discussion

261 The main objective of this work was to describe the global impact of the
262 COVID-19 epidemic among the workers of a second level hospital located in an
263 urban population in one of the areas with the highest incidence in Spain[13].
264 There have been two data sources: a cross-sectional study of seroprevalence by

265 measuring the proportion of IgG and IgM antibodies against SARS-CoV-2 in all
266 hospital personnel and a longitudinal study of the incidence of infection among
267 those HCW who had consulted for symptoms compatible with COVID-19 infection
268 and/or unsafe contact or exposure to a confirmed case. As it has been shown in
269 the results, the combination of both data sources has allowed us to have a more
270 complete picture of the pandemic impact in our center, since there have been up
271 to 74 patients (3% of the total HCW) who have had a confirmed infection by a
272 positive rRT-PCR but have not seroconverted; and otherwise there were 151
273 workers (6.2%) in whom the virus had not been detected nor had compatible
274 symptoms, but an IgG antibody has been detected.

275 The cumulative prevalence of SARS-CoV-2 infection in our center has been
276 of 19.9 %. This proportion is significantly higher than that of the population in the
277 area in which the center is located (11.4%), as stated in the wide sero-
278 epidemiological study ENE-COVID19(13), despite the fact that symptomatic
279 cases have followed a very similar onset kinetics (Fig 1). It is very likely that there
280 has been a common source of contagion with that of the general population, but
281 also it is clear that there has also been a risk exposure, especially in the first days
282 of the outbreak when the virus situation was not exactly known and HCW were
283 not taking the appropriate protective measures[14].

284 There have been several recent publications that have reported different data
285 of infection that affects healthcare personnel. Korth et al have published an
286 estimated seroprevalence in a German center of only 1.6%[15]. A hospital-wide
287 survey in Belgium rendered a 6.4% of seroprevalence[16]. In another Spanish
288 reference center in Barcelona, a cumulative prevalence has been calculated in
289 578 hospital workers through the detection of IgG, IgM and IgA and viral RNA of

290 11.6%, very similar to the population in which it is found[17]. On the contrary, in
291 other sero-epidemiological study in a nearby hospital center, a seroprevalence of
292 31.6% has been reported, a much higher level of infection than expected[18].
293 Although the population assigned to this center has a cumulative incidence higher
294 than that of our center, 1,133.63 vs. 845.12 cases/100,000 inhabitants (a 26%
295 higher incidence rate)[19], it exceeds the prevalence we have found in our survey
296 by 37% (31.6 vs 19.9%). Additional data and studies are required to justify this
297 difference.

298 Among the data from our study, it is noteworthy the high number of HCW who
299 have been infected and who have not declared any COVID-19 compatible symptoms.
300 There are 163 of 411 in total (38.7%), of which there are even 12 (3%) in which
301 the virus was detected by rRT-PCR. The role of asymptomatic patients has been
302 described both in general population surveys (40-45%)[20] and in other studies
303 among healthcare personnel, but with highly variable prevalence data ranging
304 from 0.74 to 48.5%[18,21–24]. Transmission of the virus from the asymptomatic
305 cases has already been demonstrated[4,25] and the free movement of HCW is a
306 risk for new infections, both to other health personnel, patients and even the
307 community (relatives, friends, etc.). Therefore the need for continued surveillance
308 is critical, at least while community transmission of the virus continues.
309 Seroepidemiological studies are a useful tool in the identification of these
310 asymptomatic patients and in understanding the prevalence of COVID-19[26,27].

311 Participants in our survey were mainly female (78.4%). But when we stratified
312 data by sex, significant differences have been detected and more men have been
313 in contact with virus. In the 2002 SARS outbreak, it was already described that
314 men were more severely affected than women[28]. This same characteristic is

315 occurring in the COVID-19 pandemic. Men have a higher risk of being seriously
316 ill and there has even been an excess mortality associated with the male
317 sex[29,30]. Among HCW at our centre, men have been infected globally more
318 than women, although we have not registered any sign of severity. This fact has
319 also been described in other centres[18,21], but this is the first report in which the
320 proportion of SARS infections is significantly different depending on sex. The
321 cause could be related to the protection that women have by immunity
322 mechanisms linked to the X-chromosome, different levels of sex hormones and
323 levels of expression of the receptor for the angiotensin-converting enzyme 2,
324 which is one of the entrance doors of the virus in the cell[31,32].

325 Our data shows two main populations that have been especially exposed to
326 COVID-19 infectious patients. Firstly, doctors have had a higher percentage of
327 infections (25.4%) than the rest of the professional categories. Secondly, the
328 workers who have carried out their task in the medical, emergency and ICU
329 services have presented a higher prevalence (25.2%) of the infection than the
330 rest of the staff of other services. Other studies in our environment have not
331 described these differences[17,18]. On the contrary, Chen et al[21] have shown
332 that while exposed to COVID-19 patients, doctors might have higher risk of
333 seroconversion, compared with HCW exposed to colleagues, but this difference
334 was also observed between nurses and general services assistants. It is evident
335 that among HCW with higher prevalence there has been a greater exposure to
336 infectious patients[18]. It is probably that personal protection measures could not
337 have been used properly in the first days of the epidemic but personal protection
338 equipment shortages also occurred, which is a direct cause of HCW infection[33].

339 Our study presents some pitfalls that deserve further comments. First,
340 although the participation rate has been 80.9%, a selection bias could have been
341 introduced. Nevertheless, this participation rate is higher than that reported in
342 other similar studies[16,18,34]. In addition, all professional categories and age
343 ranges have been represented. Secondly, a professional who has fallen ill and
344 may have consulted at other health centre or primary care facility and not at the
345 OHS, would have introduced a new bias. Instead, we could be aware of this
346 information since the sick leave was processed at our hospital Occupational
347 Health department. Finally, some doubts have been raised about the
348 performance of the serological and molecular diagnostic tools employed, since
349 there have been 74 workers who have been infected but have not seroconverted
350 and 11 people who have presented symptoms and have been seroconverted but
351 have not been diagnosed by rRT-PCR. These results could have underestimated
352 the real impact of the pandemic in our study population. However, serum IgG
353 antibody detection have been validated by other researchers with excellent
354 results[35,36]; and on the other hand, the molecular tool used is a standard
355 technique recommended by the main diagnostic protocols and widely applied
356 throughout the world[37].

357 **Conclusions**

358 In conclusion, the global impact of the COVID-19 pandemic on HCW of our
359 centre has been 19.9%. This prevalence has been significantly higher than
360 general population. Similarly, doctors and medical services personnel have had
361 the highest prevalence of SARS-CoV-2 infection, but many of them have not
362 presented compatible symptoms. This emphasizes the importance of the
363 performance of continuous surveillance methods of the most exposed health

364 personnel and not only based on the appearance of symptoms. These methods
365 should include both antibody and viral detection methods to have a more realistic
366 picture of the virus circulation in a certain population.

367 **Acknowledgments**

368 Our deep acknowledgment to all the staff of the Hospital Universitario de
369 Fuenlabrada for their tireless fight against the pandemic. Thanks to all the
370 volunteers who have participated in this study. We would also like to appreciate
371 the staff of the laboratory for their excellent technical assistance.

372 **References**

- 373 1. Ren L-L, Wang Y-M, Wu Z-Q, Xiang Z-C, Guo L, Xu T, et al. Identification
374 of a novel coronavirus causing severe pneumonia in human. Chin Med J
375 (Engl) [Internet]. 2020 May 5 [cited 2020 Jun 13];133(9):1015–24.
376 Available from: <http://journals.lww.com/10.1097/CM9.0000000000000722>
- 377 2. Coronavirus Disease (COVID-19) Situation Reports [Internet]. [cited 2020
378 Jun 13]. Available from: [https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
379 [coronavirus-2019/situation-reports](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
- 380 3. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin,
381 transmission and clinical therapies on coronavirus disease 2019 (COVID-
382 19) outbreak- An update on the status. Vol. 7, Military Medical Research.
383 BioMed Central Ltd.; 2020.
- 384 4. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed
385 Asymptomatic Carrier Transmission of COVID-19. Vol. 323, JAMA -
386 Journal of the American Medical Association. American Medical

- 387 Association; 2020. p. 1406–7.
- 388 5. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The
389 incubation period of coronavirus disease 2019 (CoVID-19) from publicly
390 reported confirmed cases: Estimation and application. *Ann Intern Med.*
391 2020 May 5;172(9):577–82.
- 392 6. Zhou T, Liu Q, Yang Z, Liao J, Yang K, Bai W, et al. Preliminary
393 prediction of the basic reproduction number of the Wuhan novel
394 coronavirus 2019-nCoV. *J Evid Based Med.* 2020 Feb 1;13(1):3–7.
- 395 7. Zhang Z, Liu S, Xiang M, Li S, Zhao D, Huang C, et al. Protecting
396 healthcare personnel from 2019-nCoV infection risks: lessons and
397 suggestions. Vol. 14, *Frontiers of Medicine*. Higher Education Press;
398 2020. p. 229–31.
- 399 8. Ehrlich H, McKenney M, Elkbuli A. Protecting our healthcare workers
400 during the COVID-19 pandemic. *American Journal of Emergency*
401 *Medicine*. W.B. Saunders; 2020.
- 402 9. Informe sobre la situación de COVID-19 en personal sanitario en España
403 [Internet]. [cited 2020 Jun 13]. Available from:
404 [https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENA](https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes)
405 [VE/EnfermedadesTransmisibles/Documents/INFORMES/Informes](https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes)
406 [COVID-19/COVID-19 en España. Situación en Sanitarios a 21 de mayo](https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes)
407 [de 2020.pdf](https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes)
- 408 10. Hospital Universitario de Fuenlabrada [Internet]. [cited 2020 May 25].
409 Available from:
410 <https://www.comunidad.madrid/hospital/fuenlabrada/ciudadanos/hospital->

- 411 cifras
- 412 11. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical
413 features of the emerging 2019 novel coronavirus pneumonia (COVID-19)
414 implicate special control measures. J Med Virol [Internet]. 2020 Jun 29
415 [cited 2020 Jun 6];92(6):568–76. Available from:
416 <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25748>
- 417 12. Centro Nacional de Epidemiología. RENAVE [Internet]. [cited 2020 Jun
418 30]. Available from: <https://cnecovid.isciii.es/>
- 419 13. Instituto Salud Carlos III. National Study of SARS-CoV2 sero-
420 Epidemiology in Spain (ENE-Covid19) [Internet]. [cited 2020 Jun 9].
421 Available from: <https://portalcne.isciii.es/enecovid19/>
- 422 14. Heinzerling A, Stuckey MJ, Scheuer T, Xu K, Perkins KM, Resseger H, et
423 al. Transmission of COVID-19 to Health Care Personnel During
424 Exposures to a Hospitalized Patient — Solano County, California,
425 February 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2020 Apr 17
426 [cited 2020 Jun 14];69(15):472–6. Available from:
427 [http://www.cdc.gov/mmwr/volumes/69/wr/mm6915e5.htm?s_cid=mm6915](http://www.cdc.gov/mmwr/volumes/69/wr/mm6915e5.htm?s_cid=mm6915e5_w)
428 e5_w
- 429 15. Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, et al.
430 SARS-CoV-2-specific antibody detection in healthcare workers in
431 Germany with direct contact to COVID-19 patients. J Clin Virol. 2020 Jul
432 1;128:104437.
- 433 16. Steensels D, Oris E, Coninx L, Nuyens D, Delforge M-L, Vermeersch P,
434 et al. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a

- 435 Tertiary Center in Belgium. JAMA [Internet]. 2020 Jun 15 [cited 2020 Jun
436 25]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32539107>
- 437 17. Garcia-basteiro AL, Moncunill G, Tortajada M, Vidal M, Santano R, Sanz
438 S, et al. Seroprevalence of antibodies against SARS-CoV-2 among health
439 care workers in a large Spanish reference hospital. medRxiv. 2020 May
440 2;1–36.
- 441 18. Galan I, Velasco M, Casas ML, Goyanes MJ, Rodriguez-Caravaca G,
442 Losa JE, et al. SARS-CoV-2 seroprevalence among all workers in a
443 teaching hospital in Spain: unmasking the risk. medRxiv. 2020 May
444 29;2020.05.29.20116731.
- 445 19. Servicio de Epidemiología Comunidad de Madrid. Informe epidemiológico
446 semanal comunidad de madrid. Semana 23. Available from:
447 <https://www.comunidad.madrid/servicios/salud/vigilancia-epidemiologica>
- 448 20. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection:
449 A Narrative Review. Ann Intern Med [Internet]. 2020 Jun 3 [cited 2020 Jun
450 15]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32491919>
- 451 21. Chen Y, Tong X, Wang J, Huang W, Yin S, Huang R, et al. High SARS-
452 CoV-2 Antibody Prevalence among Healthcare Workers Exposed to
453 COVID-19 Patients. J Infect [Internet]. 2020 Jun 3 [cited 2020 Jun 15];
454 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32504745>
- 455 22. Felice C, Di Tanna GL, Zanus G, Grossi U. Impact of COVID-19 Outbreak
456 on Healthcare Workers in Italy: Results from a National E-Survey. J
457 Community Health [Internet]. 2020 [cited 2020 Jun 15];1–9. Available
458 from: <http://link.springer.com/10.1007/s10900-020-00845-5>

- 459 23. Lai X, Wang M, Qin C, Tan L, Ran L, Chen D, et al. Coronavirus Disease
460 2019 (COVID-2019) Infection Among Health Care Workers and
461 Implications for Prevention Measures in a Tertiary Hospital in Wuhan,
462 China. *JAMA Netw Open* [Internet]. 2020 [cited 2020 Jun
463 15];3(5):e209666. Available from:
464 <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2766227>
- 465 24. Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, et al.
466 Screening of healthcare workers for SARS-CoV-2 highlights the role of
467 asymptomatic carriage in COVID-19 transmission. *Elife*. 2020 May 11;9.
- 468 25. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et
469 al. Transmission of 2019-NCOV infection from an asymptomatic contact
470 in Germany. Vol. 382, *New England Journal of Medicine*. Massachusetts
471 Medical Society; 2020. p. 970–1.
- 472 26. Evans S, Agnew E, Vynnycky E, Robotham J. The impact of testing and
473 infection prevention and control strategies on within-hospital transmission
474 dynamics of COVID-19 in English hospitals. [cited 2020 Jun 16]; Available
475 from: <https://doi.org/10.1101/2020.05.12.20095562>
- 476 27. Black JRM, Bailey C, Przewrocka J, Dijkstra KK, Swanton C. COVID-19:
477 the case for health-care worker screening to prevent hospital
478 transmission. Vol. 395, *The Lancet*. Lancet Publishing Group; 2020. p.
479 1418–20.
- 480 28. Karlberg J, Chong DSY, Lai WYY. Do Men Have a Higher Case Fatality
481 Rate of Severe Acute Respiratory Syndrome than Women Do? *Am J*
482 *Epidemiol* Hopkins Bloom Sch Public Heal All rights Reserv [Internet].

- 483 2004 [cited 2020 Jun 16];159(3):229–31. Available from:
484 http://www.info.gov.hk/info/sars/e_news.htm
- 485 29. Meng Y, Wu P, Lu W, Liu K, Ma K, Huang L, et al. Sex-specific clinical
486 characteristics and prognosis of coronavirus disease-19 infection in
487 Wuhan, China: A retrospective study of 168 severe patients. PLoS
488 Pathog. 2020 Apr 1;16(4).
- 489 30. Michelozzi P, de’Donato F, Scortichini M, De Sario M, Noccioli F, Rossi P,
490 et al. Mortality impacts of the coronavirus disease (COVID-19) outbreak
491 by sex and age: rapid mortality surveillance system, Italy, 1 February to
492 18 April 2020. Euro Surveill. 2020 May 1;25(19).
- 493 31. Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women
494 less than men: clinical response to viral infection. Vol. 34, Journal of
495 biological regulators and homeostatic agents. NLM (Medline); 2020.
- 496 32. Gargaglioni LH, Marques DA. Let’s talk about sex in the context of
497 COVID-19. J Appl Physiol [Internet]. 2020 Jun 1 [cited 2020 Jun
498 16];128(6):1533–8. Available from:
499 <https://journals.physiology.org/doi/10.1152/jappphysiol.00335.2020>
- 500 33. Ha JF. The covid-19 pandemic, personal protective equipment, and
501 respirator: a narrative review. Int J Clin Pract [Internet]. 2020 Jun 8 [cited
502 2020 Jun 17];e13578. Available from:
503 <http://www.ncbi.nlm.nih.gov/pubmed/32511834>
- 504 34. Paderno A, Fior M, Berretti G, Schreiber A, Grammatica A, Mattavelli D,
505 et al. SARS-CoV-2 Infection in Health Care Workers: Cross-sectional
506 Analysis of an Otolaryngology Unit. Otolaryngol Neck Surg [Internet].

- 507 2020 Jun 2 [cited 2020 Jun 14];019459982093216. Available from:
508 <http://journals.sagepub.com/doi/10.1177/0194599820932162>
- 509 35. Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. Analytical
510 performances of a chemiluminescence immunoassay for SARS-CoV-2
511 IgM/IgG and antibody kinetics. Clin Chem Lab Med [Internet]. 2020 Jul 1
512 [cited 2020 Jun 27];58(7). Available from:
513 <https://pubmed.ncbi.nlm.nih.gov/32301749/>
- 514 36. Lippi G, Salvagno GL, Pegoraro M, Militello V, Caloi C, Peretti A, et al.
515 Assessment of immune response to SARS-CoV-2 with fully automated
516 MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays
517 [Internet]. Vol. 58, Clinical Chemistry and Laboratory Medicine. De
518 Gruyter; 2020 [cited 2020 Jun 30]. p. 1156–9. Available from:
519 <https://www.degruyter.com/view/journals/cclm/58/7/article-p1156.xml>
- 520 37. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al.
521 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.
522 Eurosurveillance [Internet]. 2020 Jan 23 [cited 2020 Jun 27];25(3).
523 Available from: [/pmc/articles/PMC6988269/?report=abstract](https://pmc/articles/PMC6988269/?report=abstract)
524